These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 38790090

  • 1. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N.
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P.
    Cochrane Database Syst Rev; 2013 Dec 11; (12):CD008337. PubMed ID: 24338763
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Ju KP, Kong QZ, Li YY, Li YQ.
    Helicobacter; 2024 Dec 11; 29(1):e13054. PubMed ID: 38900537
    [Abstract] [Full Text] [Related]

  • 12. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ, Singh TP, Wei X, Yao H, Wang HL.
    Helicobacter; 2017 Dec 11; 22(6):. PubMed ID: 28884937
    [Abstract] [Full Text] [Related]

  • 13. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S.
    Intern Med; 2017 Dec 11; 56(11):1277-1285. PubMed ID: 28566587
    [Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C, Buranathawornsom A.
    J Gastroenterol Hepatol; 2021 Dec 11; 36(12):3308-3313. PubMed ID: 34622504
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial.
    Chiu YT, Lee FJ, Kuo CY, Chen YT, Lin YC, Liang KS, Wu CY, Lin RT, Lin JT, Chang CY.
    Helicobacter; 2024 Dec 11; 29(4):e13129. PubMed ID: 39164808
    [Abstract] [Full Text] [Related]

  • 17. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H.
    Helicobacter; 2018 Aug 11; 23(4):e12495. PubMed ID: 29873436
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
    Sun Y, Yue L, Hu W.
    Eur J Clin Pharmacol; 2023 Feb 11; 79(2):279-288. PubMed ID: 36527456
    [Abstract] [Full Text] [Related]

  • 19. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study.
    Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH.
    World J Gastroenterol; 2024 Jul 21; 30(27):3304-3313. PubMed ID: 39086752
    [Abstract] [Full Text] [Related]

  • 20. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct 21; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.